PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportstriple negative breast neoplasms
MeSH D064726 - triple negative breast neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001943:Breast neoplasms
191 Companies
84 Drugs
$
Success rate
D064726: 
Triple negative breast neoplasms
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Gilead SciencesSacituzumab govitecan Trodelvy  2020-04-22 $1,259 M Q4/23-Q3/24 
Clinical Trials
Historical Success Rate
Phase 1
72%
116/161
Phase 2
26%
49/186
Phase 3
9%
6/64
Approved: 4Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Gilead Sciences
Sacituzumab govitecan,
Sacituzumab govitecan-hziy,
Sacituzumab,
Rucaparib,
Transplatin,
Rucaparib camsylate,
Tbo-filgrastim,
Albumin,
Antithrombin iii,
Magrolimab,
Ivuxolimab,
Utomilumab,
Zimberelimab,
Lucitanib,
Lenograstim,
Ademetionine,
Edrecolomab,
Nepidermin,
Caelyx,
Doxorubin,
Mk3475,
Al3810,
Gcsf,
Arm1,
Hydroxydaunomycin,
Arm2,
E7389,
Nvb
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use